Related patterns have been reported in MET-driven NSCLC, where NF1 alterations were associated with reduced sensitivity to crizotinib/tepotinib via sustained ERK signaling; however, direct evidence in HCC remains limited (Tao et al., 2020; Rotow et al., 2020). The gene discussed is NF1; the disease is hepatocellular carcinoma.